The Zhitong Finance App learned that Tengsheng Pharmaceutical-B (02137) fell by more than 26%, and the intraday low of HK$1.22 hit a new low since listing. As of press release, it decreased by 26.47% to HK$1.25, with a turnover of HK$20.313,900.
According to the news, according to the Hong Kong Stock Exchange and the Hong Kong Stock Exchange's adjustment announcements issued by the Shanghai Stock Exchange and the Shenzhen Stock Exchange, Tengsheng Pharmaceuticals has been removed from the Hong Kong Stock Connect list, which will take effect today. According to reports, Tengsheng Pharmaceutical announced the discontinuation of production of the COVID-19 neutralizing antibody last year. It is its only commercial product, contributing all of its revenue in 2022. In 2022, the company lost 484 million yuan and spent 441 million yuan on R&D.